Abstract 4CPS-174 Table 2

Safety profile of CKI

Most frequent AE, any grade(%)AE grade >=3(%)Discontinuation due to toxicity(%)Mean ± SD of AE per patient
Abemaciclib Diarrhoea(75%)
Fatigue(55%)
Neutropenia(45%)
35 25 4.2 ± 2.4 (0–9)
Palbociclib Neutropenia(80.3%)
Fatigue(72.1%) Arthralgia/myalgia(24.6%)
62.3 9.8 4.1 ± 2.2 (0–9)
Ribociclib Neutropenia(81.8%)
Fatigue(54.4%) Arthralgia/myalgia(31.8%)
63.6 13.6 3.8 ± 1.6 (1–6)